In Europe, the launch of the Janssen coronavirus vaccine produced by the American company Johnson & Johnson has been postponed. The reason for this was information disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received the COVID-19 vaccine. On Tuesday, April 13, J & J company published a corresponding statement.
“In addition, we have been reviewing these cases with European health authorities. We have made the decision to proactively delay the rollout of our vaccine in Europe. We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public," the company's statement read.
Johnson & Johnson, together with European security agencies, will continue to study the cases of thrombosis among vaccinated people, as well as cooperate with experts on this issue.
Importantly, on the same day, the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) have recommended a pause in the use of the vaccine.